var data={"title":"Technetium Tc-99m tilmanocept: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Technetium Tc-99m tilmanocept: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/541610?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20322771\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Lymphoseek</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16338551\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Radiopharmaceutical</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321325\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note: </b>The route of administration, number of injections, and total injection volume per patient will vary depending on cancer and planned injection technique.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Breast cancer lymphatic mapping:</b> Intradermal, SubQ, subareolar, or peritumoral: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative lymphatic mapping</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Melanoma lymphatic mapping:</b> Intradermal or SubQ: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative lymphatic mapping</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Oral cavity squamous cell carcinoma  sentinel lymph node biopsy:</b> Peritumoral: 18.5 MBq (0.5 mCi) as radioactivity dose and 50 mcg as a mass dose at least 15 minutes prior to intraoperative sentinel node biopsy</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321326\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321327\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321328\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20323579\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Injection, powder for reconstitution [kit]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lymphoseek: Tilmanocept 250 mcg (5s) [vial contents to be combined with Technetium Tc 99m pertechnetate sodium (not included)]</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321305\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321335\" class=\"block accres drugH1Div\"><span class=\"drugH1\">Prescribing and Access Restrictions</span>\n    <p style=\"text-indent:0em;display:inline\">Lymphoseek may only be obtained through Cardinal Health&rsquo;s Nuclear Pharmacy Services.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321329\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Route of administration (intradermal, subcutaneous, subareolar, or peritumoral) is determined by cancer and planned injection technique; dose may be administered as a single injection or as multiple injections.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Breast cancer lymphatic mapping: May be administered by intradermal, subQ, subareolar, or peritumoral injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Melanoma lymphatic mapping: May be administered by intradermal or subQ injection.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Oral cavity squamous cell carcinoma  sentinel lymph node biopsy:  May be administered by peritumoral injection (Marcinow, 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Administer at least 15 minutes prior to intraoperative lymphatic mapping and sentinel lymph node biopsy; do not delay mapping or sentinel node biopsy more than 15 hours beyond administration. Use a handheld gamma counter to identify radioactivity concentrated within lymph nodes (refer to manufacturer&rsquo;s instructions for further details). Avoid injections into biopsy wound areas with evidence of edema or inflammation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Radiopharmaceutical; use appropriate precautions for handling and disposal. Use waterproof gloves and effective radiation shielding when handling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16338553\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Diagnostic imaging:</b> Radioactive diagnostic agent indicated with or without scintigraphic imaging (using a handheld gamma counter) for:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Lymphatic mapping to locate lymph nodes draining a primary tumor site in patients with solid tumors for which this procedure is a component of intraoperative management.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">- Guiding sentinel lymph node biopsy in patients with clinically node negative squamous cell carcinoma of the oral cavity, breast cancer, or melanoma.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16338549\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Radiopharmaceutical: Use appropriate precaution for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use under supervision of experienced personnel. Should be stored in original lead container or adequate radiation shield.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20322940\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">&lt;1%: Irritation at injection site, pain at injection site</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321310\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">There are no contraindications listed in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321311\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Hypersensitivity reactions with technetium Tc 99m tilmanocept may be possible (due to a chemical similarity to dextran), although no serious cases of hypersensitivity were reported in clinical trials. Medications and equipment for management of hypersensitivity should be available during administration.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Malignancy: Radiating-emitting products may increase the risk for cancer, particularly in children.   </p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special handling:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Radiopharmaceutical: Use appropriate precautions for handling, disposal, and minimizing exposure to patients and healthcare personnel. Use only under supervision of individuals with experience/training in the handling of radioactive materials approved by the applicable regulatory authority.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: Intended to supplement palpation, visual inspection, and other traditional lymph node localization procedures. Lymphatic drainage and function may be altered by prior surgery, radiation, edema, inflammation, or metastatic disease. Alterations in the lymphatic system may result in changes to node localization. Avoid injections into biopsy wound areas with evidence of edema or inflammation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344385\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20344383\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=88729&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Local Anesthetics: May diminish the diagnostic effect of Technetium Tc 99m Tilmanocept. Management: Avoid mixing and simultaneously co-injecting technetium Tc 99m tilmanocept with local anesthetics.  This interaction does not appear to apply to other uses of these agents in combination.<b> Exceptions: </b>Benzocaine; Benzydamine; Cocaine (Topical); Dibucaine; Dyclonine; Ethyl Chloride; Hexylresorcinol; Lidocaine (Ophthalmic); Lidocaine (Topical); Pramoxine; Proparacaine; Tetracaine (Ophthalmic); Tetracaine (Topical).<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321306\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321307\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Unbound technetium crosses the placenta. Technetium Tc 99m can be detected in fetal tissue; the amount depends upon the specific formulation, route of administration, and stage of pregnancy (Adelstein, 1999).  </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">In general, the potential for a radiopharmaceutical to cause fetal harm depends on the dose absorbed by the fetus and the stage of pregnancy. High doses of radiopharmaceuticals used for therapeutic procedures are more likely to result in fetal harm. A medically required diagnostic procedure can usually be modified to decrease fetal risk. Elective diagnostic procedures should be delayed until after delivery (Adelstein, 1999; ICRP, 2000; Parker, 2004). Pregnancy status should be determined in women of childbearing potential (Parker, 2004). The manufacturer recommends that in women of reproductive potential, administer within 10 days following onset of menses or obtain pregnancy test within 48 hours prior to administration. </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321309\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Technetium Tc 99m is excreted into breast milk; information specific to technetium Tc 99m tilmanocept has not been located. Based on clearance, the manufacturer recommends that patients should pump and discard breast milk for at least 60 hours after administration. </p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Following the administration of a radiopharmaceutical, women with a well-established milk supply should pump at normal feeding times and discard the milk until breast-feeding may be resumed (Harding, 1995; Mountford, 1989). Excretion of technetium Tc 99m into colostrum is widely variable and information is limited; therefore, recommendations related to early breast-feeding cannot be made (Mountford, 1989; Rubow, 1994). Elective diagnostic procedures should be delayed until breast-feeding has stopped (Parker, 2004). Depending on the dose, compliance with regulatory requirements for instructions to the patient and recordkeeping may also be applicable (US NRC, 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321316\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Radioactive diagnostic agent which accumulates in lymphatic tissue and binds (selectively) to a mannose binding receptor (CD206) on macrophage and dendritic cell surfaces.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20321318\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Detectable in lymph nodes within 10 minutes (wait at least 15 minutes before mapping)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Duration: Has been detected for up to 30 hours after administration (mapping should be conducted within 15 hours following administration)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: Radioactivity also distributes to liver, kidney, and bladder (accumulated radioactive dose reached a maximum at 1 hour after administration and was ~1% to 2% of injected dose in each tissue)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination at injection site: 1.8-3.1 hours</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27529498\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Lymphoseek (AT, CZ, DK, EE, IE, LT, MT, PL, PT, SK)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Adelstein SJ, &quot;Administered Radionuclides in Pregnancy,&quot; <i>Teratology</i>, 1999, 59(4):236-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/10331526/pubmed\" target=\"_blank\" id=\"10331526\">10331526</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Harding LK, Bossuyt S, Pellet C, et al, &quot;Recommendations for Nuclear Medicine Physicians Regarding Breastfeeding Mothers,&quot; <i>Eur J Nucl Med</i>, 1995, 22(5)BP17.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    International Commission on Radiological Protection (ICRP), &quot;Pregnancy and Medical Radiation,&quot; <i>Ann ICRP</i>, 2000, 30(1):iii-viii, 1-43.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/11108925/pubmed\" target=\"_blank\" id=\"11108925\">11108925</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Leong SP, Kim J, Ross M, et al, &ldquo;A Phase 2 Study of <sup>99m</sup>Tc-Tilmanocept in the Detection of Sentinel Lymph Nodes in Melanoma and Breast Cancer,&rdquo; <i>Ann Surg Oncol</i>, 2011, 18(4):961-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/21331809/pubmed\" target=\"_blank\" id=\"21331809\">21331809</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lymphoseek (technetium Tc 99m tilmanocept) [prescribing information]. Dublin, OH: Navidea Biopharmaceuticals; February, 2013 .</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lymphoseek (technetium Tc 99m tilmanocept) injection [prescribing information]. Dublin, OH: Navidea Biopharmaceuticals; September 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Marcinow AM, Hall N, Byrum E, et al. Use of a novel receptor-targeted (CD206) radiotracer, 99mTc-tilmanocept, and SPECT/CT for sentinel lymph node detection in oral cavity squamous cell carcinoma: initial institutional report in an ongoing phase 3 study. <i>JAMA Otolaryngol Head Neck Surg</i>. 2013;139(9):895-902.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/24051744/pubmed\" target=\"_blank\" id=\"24051744\">24051744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mountford PJ and Coakley AJ, &quot;A Review of the Secretion of Radioactivity in Human Breast Milk: Data, Quantitative Analysis and Recommendations,&quot; <i>Nucl Med Commun</i>, 1989, 10(1):15-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/2645546/pubmed\" target=\"_blank\" id=\"2645546\">2645546</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JA, Daube-Witherspoon ME, Graham LS, et al, &quot;Procedure Guideline for General Imaging: 3.0,&quot; Society of Nuclear Medicine, 2004. Available at  http://interactive.snm.org/docs/General_Imaging_v3.0.pdf</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Rubow S, Klopper J, Wasserman H, et al, &quot;The Excretion of Radiopharmaceuticals in Human Breast Milk: Additional Data and Dosimetry,&quot; <i>Eur J Nucl Med</i>, 1994, 21(2):144-53.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/8162938/pubmed\" target=\"_blank\" id=\"8162938\">8162938</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sondak VK, King DW, Zager JS, et al, &ldquo;Combined Analysis of Phase III Trials Evaluating [<sup>99m</sup>Tc] Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneous Melanoma,&rdquo; <i>Ann Surg Oncol</i>, 2013, 20(2):680-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/23054107/pubmed\" target=\"_blank\" id=\"23054107\">23054107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    U.S. Nuclear Regulatory Commission (USNRC), &quot;Regulatory Guide 8.39. Release of Patients Administered Radioactive Materials,&quot; 1997.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wallace AM, Han LK, Povoski SP, et al, &ldquo;Comparative Evaluation of [<sup>99m</sup>Tc] Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer Patients: Results of Two Phase 3 Trials,&rdquo; <i>Ann Surg Oncol</i>, 2013, 20(8):2590-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/technetium-tc-99m-tilmanocept-drug-information/abstract-text/23504141/pubmed\" target=\"_blank\" id=\"23504141\">23504141</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 88729 Version 42.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F20322771\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F16338551\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F20321325\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F20321326\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F20321327\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F20321328\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F20323579\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F20321305\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Prescribing and Access Restrictions\" href=\"#F20321335\" class=\"outlineLink\">Prescribing and Access Restrictions</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F20321329\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F16338553\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F16338549\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F20322940\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F20321310\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F20321311\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F20344385\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F20344383\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F20321306\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F20321307\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20321309\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F20321316\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F20321318\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F27529498\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/88729|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}